Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders held by Proteon Therapeutics, Inc. on June 20, 2017. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events rather than financial performance.
Material Changes
No material financial changes are reported in this document. The primary event is the completion of the annual stockholder meeting.
Outlook, Risks, and Corporate Actions
- Director Elections: Stockholders elected all nominees for directors. Scott A. Canute and Tim Haines received significant "For" votes (approximately 11 million each) with minimal "Withheld" votes.
- Auditor Ratification: Stockholders ratified the appointment of Ernst and Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
- Voting Results: The ratification of the auditor received 15,329,819 votes "For," 15,079 "Against," and 23,366 "Abstentions."
Investor Verification Checklist
- Verify the full slate of directors elected at the June 20, 2017 meeting.
- Confirm the engagement of Ernst and Young LLP for the 2017 fiscal year audit.
- Review the company's most recent 10-K or 10-Q for financial data, as this 8-K contains no financial metrics.